Research led by Vassilios Papadopoulos, DPharm, PhD, dean of the USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, indicates that a cholesterol-binding protein may be the key to stopping a subtype of nonalcoholic fatty liver disease by shutting down multiple pathways of progression, so the liver can heal and regenerate.

Until recently, the only treatment options for this type of liver disease were diet and lifestyle changes. Even the first drug approved by the Food and Drug Administration, rezdiffra, only targets one aspect of the disease by activating a thyroid hormone receptor that reduces liver fat accumulation.

To read the full story, click here.